ALK and non-small cell lung carcinoma: Later generations of ALK inhibitors, such as brigatinib, ceritinib, alectinib, and lorlatinib, have demonstrated significant efficacy in the treatment of non-small cell lung cancer, by substantially prolonging PFS and overcoming resistance mechanisms [74,75,76,77].